Here is a list of cutting edge, smallcap biotech stocks we own and in order!

 

Generative AI is transforming healthcare faster than almost any other sector, according to a new McKinsey report

Here is a ranked analysis of cutting edge healthcare/pharmaceutical smallcaps, based on (1) proximity to a breakout therapy and (2) investment attractiveness as of now — combining clinical pipeline momentum, FDA progress, partnerships, recent data, and stock performance potential.

---

🔬 Ranked by Breakout Therapy Proximity

This is based on the likelihood of a near-term breakthrough therapy (FDA fast-track, pivotal results, major data readouts).

Rank	Ticker	Company	Breakout Potential Highlights
1	VKTX	Viking Therapeutics	Breakthrough obesity/NASH drug (VK2809, VK2735) with massive upside in GLP-1/obesity boom. Phase 2 data strong; entering late-stage.
2	CABA	Cabaletta Bio	Autoimmune pipeline (CABA-201) showing transformative early results in lupus and other autoimmune diseases. Similar strategy to CAR-T, now with safety upside.
3	NTLA	Intellia Therapeutics	In vivo CRISPR for ATTR and hereditary angioedema (HAE). First-ever systemic CRISPR success in humans. Pivotal trials advancing.
4	CRSP	CRISPR Therapeutics	Exa-cel approved for SCD and TDT (partnered with Vertex); potential for next-gen CRISPR 2.0 programs. Already a breakout, but priced in.
5	BEAM	Beam Therapeutics	Base editing platform; BEAM-101 for SCD in Phase 1/2; AATD candidate recently dosed. Long runway but slower than CRISPR/NTLA.
6	VERVE	Verve Therapeutics	Base editing for cardiovascular diseases (e.g. PCSK9, ANGPTL3). First-in-human data still early, but long-term potential.
7	ARCT	Arcturus Therapeutics	Self-amplifying mRNA platform. Has vaccine deals (Meiji, CSL) and cystic fibrosis program in preclinical. Earlier stage, undervalued.
8	PHAT	Phathom Pharmaceuticals	Gastrointestinal therapies (e.g. Vonoprazan) targeting acid-related disorders. Recently got FDA approval — modest market.
9	IMMX	Immix Biopharma	Early-stage oncology and rare disease company. Some interesting candidates, but very speculative at this point.

---

💰 Ranked by Investment Attractiveness Right Now

Factoring in upside potential, stock price discount, market trends (GLP-1s, gene editing), and partnerships.

Rank	Ticker	Reasons to Consider Buying Now
1	VKTX	Best GLP-1/NASH play outside of LLY/NVO. Stock is below recent highs. Phase 3 path = massive upside.
2	CABA	Autoimmune breakthrough potential. Stock pulled back after big run = possible entry. Partnered with BMS.
3	NTLA	Undervalued after pullback; ATTR and HAE pipeline solid. First-mover advantage in in vivo editing.
4	ARCT	Undervalued RNA tech with global partners. COVID mRNA success + pipeline optionality.
5	CRSP	Already approved drug; priced in, but pipeline optionality and Vertex partnership still strong.
6	BEAM	Long-term value play. Base editing unique, but needs human data.
7	PHAT	Revenue coming in from recent approvals, but upside more limited. Good as a value biotech.
8	VERVE	Promising pipeline, but long timeline. Recent safety setbacks = wait for reentry.
9	IMMX	Pure speculation. If investing, do so in very small amounts or avoid unless speculative appetite is high.

---

🧪 Conclusion – Top 3 Right Now:

1. VKTX – Leading obesity/NASH contender; huge upside, fast-moving.

2. CABA – Emerging autoimmune disruptor; next-gen cell therapy.

3. NTLA – First-in-class CRISPR success; attractive valuation now.

Here’s a suggested portfolio weighting if you're investing across these nine biotech stocks, with emphasis on balancing breakthrough potential, clinical proximity, market trends (e.g., GLP-1/NASH, gene editing), and risk-adjusted upside:

---

🎯 Suggested Portfolio Allocation (100%)

Ticker	Company	Weight (%)	Rationale
VKTX	Viking Therapeutics	22%	Flagship position. Strong GLP-1/NASH pipeline with large-market potential and near-term catalysts.
CABA	Cabaletta Bio	18%	High-upside autoimmune play. Early but transformative CAR-T-like therapy with major big pharma interest.
NTLA	Intellia Therapeutics	15%	First-in-human systemic CRISPR success; undervalued after pullback; strong ATTR/HAE path.
CRSP	CRISPR Therapeutics	12%	Approved therapy (Exa-cel) + broad pipeline. Still solid but partially priced in.
ARCT	Arcturus Therapeutics	10%	Undervalued RNA tech; good optionality via partnerships and CF/mRNA platforms.
BEAM	Beam Therapeutics	8%	Base editing pioneer; longer-term play with promising science but needs more human data.
VERVE	Verve Therapeutics	6%	Base editing in heart disease = big TAM, but safety setbacks suggest caution for now.
PHAT	Phathom Pharmaceuticals	5%	Recently approved drug, small but growing market; value-oriented slice.
IMMX	Immix Biopharma	4%	High-risk/high-reward microcap. Small speculative exposure only.

---

🧠 Notes:

• You could simplify this into a Core + Satellite approach:

  • Core (70%): VKTX, CABA, NTLA, CRSP

  • Satellite (30%): ARCT, BEAM, VERVE, PHAT, IMMX

• If you prefer a higher-risk/reward tilt, increase weightings in CABA and ARCT, and trim CRSP or PHAT.

• If you want more defensive biotech exposure, boost PHAT or CRSP slightly, as they’re closer to revenue or approval stages.

  How Beam Therapeutics (BEAM) in collaboration with researchers at the University of Pennsylvania and Children’s Hospital of Philadelphia saved baby KJ

The first technological advance in the detection of atherosclerosis, heart disease and stroke in over 100 years awaiting FDA approval!

  (ED Note: We first posted this article 11 months ago, and feel it is even more relevant now with FDA Approval pending)

Lexington Bio Sciences (LexingtonBioSciences.com)

CSE-LNB or OTC-LXGTF 

Heart Disease and Heart Attacks are the number one killer of North Americans, and most people, worldwide. Nearly 1 in 3 deaths in the USA alone are attributed to Heart Attack and Stroke!

For 50% of these people, their "first" indication of a problem is a massive heart attack.  They have no warning whatsoever.

 

Though taking blood pressure and heart rates coupled with ultrasound techniques will sometimes indicate a problem, the fact remains that, only in 50% of all cases do these indicators work. Now, wouldn't it be great if there was a "Non-invasive" way of determining, with a lot more accuracy, if heart disease is prevalent in a patient, "before" the onset of a heart attack? Hey, wouldn't it be great if that test was no more bother than simply taking your blood pressure is?

Well, now there is such a device, currently in Clinical Trials, after 15 years of research and development in California Universities. Lexington BioSciences "HeartSentry" can measure something that has never been measured properly before. Endothelium

Endothelium, are the cells that line all arteries and are critical to the prevention of atherosclerosis, heart disease and stroke, the two leading causes of deaths worldwide (17.5 million people every year). 

The significant value of measuring endothelial function is supported by many peer-reviewed studies.

For ease of use this new, life saving technology has been incorporated into a simple blood pressure cuff.  Utilizing both blue tooth and cloud technology, the device to provide up-to-date, accurate readings of a patients complete cardiovascular health via electronic monitoring.

As you might expect, this is a significant development in a  multi-billion dollar market, and all the patents and the technology are owned by a MicroCap Business, owned and operated by PHD's

 

LexingtonBioSciences

 

 

 

 

 

About Lexington Bio Sciences - Early Detection and prevention of Heart Disease and Stroke!

The Endothelium: Getting to the “Heart” of Cardiovascular Disease

Despite positive developments in medication and lifestyle changes to reduce risk factors associated with cardiovascular disease (CVD) and atherosclerosis (plaque build-up in arteries), stroke and heart attack remain the leading cause of death worldwide.  Innovation in medical care and medical devices will likely play a central role in improving long term cardiovascular health outcomes. Over the past several years, Lexington Biosciences has focused on the health of the endothelium, which is the critical inner lining covering all blood vessels throughout the body.  We are excited to introduce the HeartSentry device as an important endothelial health measurement tool, which can serve as an early predictor in the cardiovascular disease process. From the heart to the tiniest capillary, endothelial cells form the innermost lining of the entire circulatory system. Cumulatively called the endothelium, it is composed of a single layer of cells which are critical to vascular health, and which may function as a kind-of “built-in” sensor for the vascular system. They act to guide the arteries to dilate or constrict under stress or other external stimuli. Disruption of normal endothelial function is known to be a precursor to CVD and atherosclerosis. In short, as the vascular system becomes burdened with atherosclerosis, the endothelial cells stop working as well as they did as before, which can provide a key signal that the health of the cardiovascular system has been adversely affected. A dysfunctional endothelium can be one of the earliest signs that plaque is accumulating inside arteries, which can be non-invasively observed as an inability to dilate effectively under different flow conditions or environmental stresses. Once the endothelium is disrupted and plaque starts to accumulate, it’s usually there for good – barring medical intervention. If left untreated over time, plaque will eventually increase until it blocks the artery or breaks free to enter the circulatory system. The result is typically either a heart attack or a stroke. The good news is that medication can help improve cardiovascular disease and decrease risk of catastrophic events like heart attack or stroke. Therefore monitoring endothelial function may offer an essential approach to prevent cardiovascular disease and guide treatment. This is why we have developed and positioned HeartSentry as a front line cardiovascular diagnostic device. While the above is widely acknowledged in medical circles, most of the general population aren’t aware of the importance of the endothelium because few people undergo testing for it. Testing modalities are currently limited, and often involve procedures which can be hard to perform such as flow-mediated dilation (FMD) to evaluate endothelial function. FMD measures the endothelial response during reactive hyperemia (changes in blood flow). However, it has shortcomings in that it is difficult to perform and is subject to a high degree of user dependent test variability. While the literature supports endothelial assessment as being a valuable precursor of CVD and atherosclerosis, many of the tests to evaluate it can be invasive or difficult to perform and, all too often, are not ordered until the disease has undergone significant progression. We believe that a non-invasive, reproducible, and instantaneous test of endothelial function could be a game-changer for long term cardiovascular disease prevention.   Lexington Biosciences has developed an easy-to-use device that will enable users to obtain endothelial function measurements as easily as stepping on a scale or measuring blood pressure or temperature, that can be done in a clinic or potentially even from the comfort of home.  We are optimistic that HeartSentry can help to fill this important need, advancing the field to help prevent cardiovascular diseases like heart attack and stroke.

More From Lexington BioSciences

Lexington BioSciences Inc. aims to become a leader in the development of cardiovascular measurement solutions proposed for common clinical applications with the potential for future home use. 
 

Please visit our website to watch our video, find out more about us, and subscribe to Twitter or Facebook to receive the latest news, newsletters, blog posts and more.
Join the conversation about our exciting HeartSentry product